Tegretol and Diprivan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tegretol (carbamazepine) and Diprivan (propofol). Common drug interactions include jaundice among females and pyrexia among males.

The phase IV clinical study analyzes what interactions people have when they take Tegretol and Diprivan. It is created by eHealthMe based on reports of 30 people who take the same drugs from the FDA, and is updated regularly.

What is Tegretol?

Tegretol has active ingredients of carbamazepine. It is often used in epilepsy. eHealthMe is studying from 45,969 Tegretol users. Check the latest studies of Tegretol.

What is Diprivan?

Diprivan has active ingredients of propofol. eHealthMe is studying from 6,496 Diprivan users. Check the latest studies of Diprivan.



On Jul, 28, 2026

30 people who take Tegretol and Diprivan together, and have interactions are studied.

Tegretol and Diprivan drug interactions.

What are the common drug interactions of Tegretol and Diprivan, by gender? *:

female:

  1. Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
  2. Lactic acidosis (low ph in body tissues)
  3. Livedo reticularis (a lace-like purplish discoloration of the skin)
  4. Liver disorder (liver diseases)
  5. Lymphangitis (inflammation of the lymph channel)
  6. Lymphoedema (localized fluid retention and tissue swelling)
  7. Metabolic disorder (an abnormal function and pattern of body fat. insulin resistance refers to the diminished ability of cells to respond to the action of insulin in promoting the transport of the sugar glucose, from blood into muscles and other tissues)
  8. Muscle tightness
  9. Nail disorder (disease of nail)
  10. Obstructive airways disorder (a progressive disease that makes it hard to breathe)

male:

  1. Pyrexia (fever)
  2. Drug rash with eosinophilia and systemic symptoms (adverse drug reactions with rash)
  3. Pneumonia
  4. Rash
  5. Anaemia macrocytic (a macrocytic class of anaemia)
  6. Blood uric acid increased
  7. Decubitus ulcer (a chronic ulcer of the skin caused by prolonged pressure on it)
  8. Dermatitis contact (skin reaction (dermatitis) resulting from exposure to allergens)
  9. Dysphagia (a condition in which swallowing is difficult or painful)
  10. Eczema asteatotic (severe dry skin- during the winter months and in the elderly)

What are the common drug interactions of Tegretol and Diprivan, by age (0-1 to 60+)? *:

0-1:

  1. Altered state of consciousness (altered state of mind)

2-9:

n/a

10-19:

  1. Sepsis (a severe blood infection that can lead to organ failure and death)
  2. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  3. Anaemia (lack of blood)
  4. Drug effect decreased
  5. Febrile neutropenia (fever with reduced white blood cells)
  6. Haemoglobin decreased
  7. Hemianopia homonymous (visual field defect involving either the two right or the two left halves of the visual fields of both eyes)
  8. Hyperpyrexia malignant (disease passed down through families that causes a fast rise in body temperature (fever) and severe muscle contractions- infectious)
  9. Lactic acidosis (low ph in body tissues)
  10. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)

20-29:

  1. Alanine aminotransferase increased
  2. Aspartate aminotransferase increased
  3. Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
  4. Cytolytic hepatitis (dissolution or destruction of a liver cell)
  5. Encephalitis viral (inflammation of the brain due to viral infection)
  6. Aspartate aminotransferase decreased
  7. Bicytopenia (two parameters from the full blood count are low, the term bicytopenia can be used)
  8. Blood creatine phosphokinase increased
  9. C-reactive protein increased
  10. Delayed recovery from anaesthesia

30-39:

n/a

40-49:

  1. Drug rash with eosinophilia and systemic symptoms (adverse drug reactions with rash)
  2. Rash
  3. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
  4. Drug hypersensitivity
  5. Dyspnoea (difficult or laboured respiration)
  6. Multi-organ failure (multisystem organ failure)
  7. Pyrexia (fever)
  8. Renal impairment (severely reduced kidney function)
  9. Skin exfoliation (removal of the oldest dead skin cells)
  10. Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)

50-59:

  1. Cardiac failure acute
  2. Platelet count decreased
  3. Pyrexia (fever)

60+:

  1. Anaemia macrocytic (a macrocytic class of anaemia)
  2. Blood uric acid increased
  3. Hypotonia (low muscle tone)
  4. Lymphocyte count decreased
  5. Muscle contracture (a permanent shortening of a muscle)
  6. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  7. Platelet count decreased
  8. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  9. Skin ulcer
  10. Subdural haematoma (blood collects between the skull and the surface of the brain)

What are the existing conditions these people have? *

  1. Status Epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure): 10 people, 33.33%
  2. Glioblastoma Multiforme (most common and deadliest of malignant primary brain tumours in adults): 5 people, 16.67%
  3. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 5 people, 16.67%
  4. Urinary Tract Infection: 2 people, 6.67%
  5. Skin Ulcer: 2 people, 6.67%
  6. Sedation: 2 people, 6.67%
  7. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 6.67%
  8. Muscle Contracture (a permanent shortening of a muscle): 2 people, 6.67%
  9. Herpes Zoster: 2 people, 6.67%
  10. Haemorrhoidal Haemorrhage (bleeding from the haemorrhoids): 2 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Tegretol and Diprivan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Tegretol and Diprivan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tegretol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Diprivan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tegretol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Diprivan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on carbamazepine and propofol (the active ingredients of Tegretol and Diprivan, respectively), and Tegretol and Diprivan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: